GleamWall
中文EN

PRTA PROTHENA CORP PUBLIC LTD CO

Pharmaceutical Preparations · Nasdaq · SEC CIK 1559053 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY347.4%
TTM net income YoY91.5%
TTM EPS YoY91.3%
Revenue 3-yr CAGR-27.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-64.6%
Net margin-45.4%
FCF margin—
EBITDA margin-63.1%

Returns

ROE-8.5%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.17x

Leverage & solvency

Liabilities / assets5.2%
Debt / equity0.00x
Current ratio23.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.31x
Accruals ratio2.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$620,000$1.01M$51.08M$21,000$2.42M$4.42M$2.83M$2.12M
R&D expense$8.43M$8.80M$12.63M$14.59M$28.94M$40.52M$50.81M$50.17M
SG&A expense$10.59M$10.90M$12.67M$12.65M$13.24M$15.91M$17.60M$16.85M
Operating income-$18.82M-$21.10M$30.04M-$24.20M-$40.24M-$84.62M-$65.58M-$64.90M
Pretax income-$16.51M-$18.58M$32.72M-$21.58M-$36.91M-$80.97M-$61.37M-$59.50M
Income tax$2,000$2,000$1,000$10,000-$371,000$44.80M-$1.18M-$1.54M
Net income-$16.51M-$18.58M$32.72M-$21.59M-$36.54M-$125.77M-$60.20M-$57.96M
EBITDA-$18.62M-$20.90M$30.22M-$23.98M-$40.04M-$84.42M-$65.36M-$64.68M
EPS (basic)-0.32-0.360.61—-0.68-2.34-1.12—
EPS (diluted)-0.32-0.360.60—-0.68-2.34-1.12—
Weighted avg. shares (diluted)51.44M52.15M54.11M—53.83M53.83M53.83M—
Banking
Net interest income$2.32M$2.55M$2.42M$2.65M$3.35M$3.79M$4.35M$5.39M
Balance sheet
Cash & equivalents$271.37M$288.19M$329.46M$307.53M$330.84M$371.44M$417.94M$472.25M
Receivables———————$0
Current assets$273.86M$292.01M$339.20M$315.19M$339.97M$385.48M$436.17M$485.41M
PP&E, net$2.30M$2.49M$1.96M$2.14M$2.46M$2.69M$2.87M$3.08M
Total assets$283.52M$302.58M$349.89M$326.80M$352.63M$399.07M$495.34M$547.11M
Current liabilities$11.43M$11.66M$32.52M$40.84M$51.44M$67.81M$48.46M$48.50M
Total liabilities$14.68M$15.69M$37.28M$46.33M$57.64M$74.73M$57.66M$60.18M
Shareholders' equity$268.84M$286.89M$312.62M$280.47M$294.99M$324.33M$437.68M$486.93M
Shares outstanding51.34M51.74M53.08M53.83M53.83M53.83M53.83M53.83M
Cash flow statement
Operating cash flow-$11.96M-$25.05M$28.88M-$23.31M-$40.56M-$46.34M-$53.36M-$47.77M
Investing cash flow-$73,000-$652,000$0$0-$10,000-$86,000-$42,000-$43,000
Financing cash flow-$4.79M-$15.57M-$6.95M$0-$17,000-$74,000-$48,000-$59,000
Depreciation & amortization$200,000$200,000$184,000$218,000$200,000$200,000$223,000$221,000
Stock-based compensation$6.41M$7.88M$6.92M$7.07M$7.20M$12.42M$10.95M$10.52M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.